Investments, team additions, and selected coverage of the firm.
We are delighted to welcome Franck Le Deu to Aulis as Venture Partner, helping build the Life Sciences practice in China and Asia.
We are delighted to welcome Franck Le Deu to Aulis as Venture Partner. Franck will help build the Life Sciences practice in China and Asia and bridging the West and the East and give strategic advice to the fund as well as our portfolio companies.
Aulis Capital joins EpiBiologics' $107M Series B to advance a next-generation protein degradation pipeline.
Aulis Capital is pleased to announce our investment in EpiBiologics’ $107M Series B financing. EpiBiologics is advancing a next-generation protein degradation pipeline and platform that targets extracellular membrane and soluble proteins. The Company’s proprietary EpiTAC platform is a modular bispecific antibody system that enables targeted degradation of disease-driving extracellular proteins in a tissue-specific manner.
With this financing, EpiBiologics will advance their pipeline of novel bispecific antibodies to selectively degrade disease-driving membrane and soluble targets in oncology and immunology. EpiBiologics aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas, including oncology and immunology.
#EpiBiologics #EGFR #Lungcancer #NSCLC #HNSCC
In WeChat, open Discover → Scan and point at this code to follow Aulis Capital’s official account. Your phone’s camera app won’t open it.